Halifax to initiate COVID-19 vaccine trials with CanSino Biologics

By Nikita Chaurasia  Date: 2020-05-18

Halifax to initiate COVID-19 vaccine trials with CanSino Biologics

The Dalhousie University, also known as Halifax University, located in Canada, has reportedly announced that its team would be working in collaboration with Chinese manufacturer, CanSino Biologics, to conduct the first-ever Canadian clinical trial for assessing a possible coronavirus vaccine.

The Prime Minister of Canada, Justin Trudeau made this announcement on Saturday during his daily address to the nation.

Trudeau stated that research and development require time, and should be done right. However, despite the fact, this is a good news. The National Research Council would be working closely alongside the manufacturers, so in case the clinical trials are a success, the coronavirus vaccine can be manufactured and distributed at scale.

The clinical trials have been authorized by Health Canada and would be carried out at the CCfV (Canadian Centre for Vaccinology) at the Dalhousie University, Halifax. The CCfV team comprises 45 people working together on a potential vaccine candidate from CanSino Biologics.

Health Canada, while speaking about the trial, stated that the approval for going ahead with the trial was done after a careful review of the submitted trial application, which fulfilled the necessary quality and safety requirements.

Researchers stated that approximately 600 participants would be required to commence the clinical study.

Scott Halperin, CCfV Director and professor of immunology, pediatrics, and microbiology at Dalhousie University, stated that they would be further building upon the trials that have already started in China.   

Halperin further added that a vaccine strain known as Ad5-nCoV utilizes another virus which is modified to not cause infection within humans. It expresses a COVID-19 antigen called spike protein on its surface. If the trial participants create antibodies to tackle this antigen, then the formulation might prove helpful against the coronavirus.

Halperin hopes that the clinical trials would start in the coming two weeks once the team receives its approval from the ethics board.

Less than 100 participants of different ages would be tested in Phase 1. Phase 2 is expected to have more than 500 participants ranging between 18 to 85 years of age.

 

Source credit: https://www.cbc.ca/news/canada/nova-scotia/first-canadian-vaccine-trials-covid-19-halifax-1.5573283

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

India’s Gennova Biopharmaceutical working on Omicron-specific vaccine

India’s Gennova Biopharmaceutical working on Omicron-specific vaccine

By Nikita Chaurasia

Gennova's potential mRNA vaccine is currently undergoing Phase II and Phase III trials. If approved for a EUA, it would be India’s first mRNA COVID-19 vaccine. Gennova Biopharmaceutical, a subsidiary of Pune-based drugmaker Emcure, is...

Recykal secures USD 22 Mn in a fundraise led by Morgan Stanley India

Recykal secures USD 22 Mn in a fundraise led by Morgan Stanley India

By Nikita Chaurasia

Recykal, a B2B waste management and recycling marketplace head-quartered in Hyderabad, has reportedly raised USD 22 million in funding from Morgan Stanley India. According to the company, existing investors including Circulate Capital, Arun Venkatac...

Reliance buys controlling stake in NYC hotel in its hospitality push

Reliance buys controlling stake in NYC hotel in its hospitality push

By Nikita Chaurasia

Reliance Industries Ltd. is reportedly planning to acquire a controlling stake in New York's five-star Mandarin Oriental Hotel for around USD 100 million. The company stated in a stock exchange filing that its industrial investments subsidiary, ...

India inoculates 3.8 million teens over fears of third COVID-19 wave

India inoculates 3.8 million teens over fears of third COVID-19 wave

By Nikita Chaurasia

India has reportedly vaccinated over 3.8 million teens aged between 15-18 years as of 3rd January in an effort to boost its inoculation drive to protect the large young population before the onslaught of a possible third wave of coronavirus infection...

Apple on track to become the world’s first USD 3 trillion company

Apple on track to become the world’s first USD 3 trillion company

By Nikita Chaurasia

Tech giant Apple Inc. has once again become the world’s most valuable company as it is just a hair's breadth away from a market capitalization of USD 3 trillion. On Monday, the iPhone maker’s shares slid a little over 2% to USD 175.7...